Welcome to the e-CCO Library!

P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Wagner1, J. Mansfield2, C. Geier1, A. Dash3, Y. Wang3, C. Li3, A. Lekkerkerker3, T. Lu3

Created: Thursday, 30 January 2020, 10:12 AM
P420: Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrence
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Auzolle C.*1, Houze P.2, Tran-Minh M.-L.1, Nancey S.3, Buisson A.4, Fumery M.5, Pariente B.6, Djenidi F.1, Marteau P.7, Bouhnik Y.8, Seksik P.7, Allez M.7

Created: Wednesday, 20 February 2019, 10:36 AM
P420: Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemia
Year: 2021
Source: ECCO'21 Virtual
Authors: Akriche, F.(1);Jacob, I.(2);Schmidt, C.(3);Howaldt, S.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P420: Correlation between Infliximab trough levels and endoscopic activity in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Bernardo*1, S. Fernandes1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Marinho1

Created: Friday, 22 February 2019, 9:41 AM
P420: Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Klett*, D. Strobel, D. Wildner, R. Atreya, M. F. Neurath, R. S. Görtz

Created: Friday, 22 February 2019, 9:49 AM
P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Gheorghe1, P. Svoboda2, A. Dimitriu1*, B. Mateescu3, I. Kotzev4

Created: Thursday, 21 February 2019, 9:14 AM
P420: Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
Year: 2022
Source: ECCO'22
Authors: Melotti, L.(1);Dussias, N.K.(1);Belluzzi, A.(1);Salice, M.(1);Calabrese, C.(1);Rizzello, F.(1);Gionchetti, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P420: Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Holubar, S.(1)*;Cohen, B.(2);Uchino, T.(1);Lincango, E.(1);Prien, C.(1);Joseph, A.(2);Achkar, J.P.(2);Gunter, R.(1);Lashner, B.(2);DeLaney, C.(3);Ban, K.(1);Bolshinsky, V.(1);Lipman, J.(1);Liska, D.(1);Philpott, J.(2);Naseer, M.(2);Kanters, A.(1);Braga-Neto, M.(2);Rieder, F.(2);Somovilla, J.(1);Qazi, T.(2);Regueiro, M.(2);Hull, T.(1);Steele, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Dubois, A. Moens, J. Sabino, M. Ferrante, S. Vermeire

Created: Thursday, 30 January 2020, 10:12 AM
P421: Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P421: Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn's disease
Year: 2022
Source: ECCO'22
Authors: Albshesh, A.(1);Ungar, B.(1);Kopylov, U.(1);Ben-Horin, S.(1);Carter , D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P421: Effects of combination therapy in inflammatory bowel disease: how long should we keep concomitant immunomodulators?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

Created: Friday, 22 February 2019, 9:41 AM
P421: Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liebert, A.(1);Kłopocka, M.(1);Cichoż-Lach, H.(2);Michalak, A.(2);Talar-Wojnarowska, R.(3);Domżał-Magrowska, D.(3);Filipiuk, A.(4);Krogulecki, M.(4);Kopertowska-Majchrzak, M.(5);Eder, P.(6);Stawczyk-Eder, K.(6);Waszak, K.(6);Zagórowicz, E.(7,8);Wojciechowski, K.(9,10);Drygała, S.(9)*;
Created: Friday, 14 July 2023, 11:05 AM
P421: SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Misra1, J. Curran2, H. Herfarth3, K. Jagarlamudi4, C. Oneto5, B.R. Bhandari6, G. Wiener7, D. Kerman8, A. Moss9, R. Pomerantz10, J. Zhao10, P. Bernardo10, S. Simmons10, L. Diao10, E. O’Brien10, M. Henn10, M. Trucksis10*

Created: Thursday, 21 February 2019, 9:14 AM
P421: Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Juzlova1, K. Koblova1, J. Herzogova1, M. Bortlik*2, D. Duricova2, M. Lukas2

Created: Friday, 22 February 2019, 9:49 AM
P421: Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Attauabi, M.(1,2,3);Vind, I.(1,3);Pedersen, G.(1,3);Bendtsen, F.(3);Benedict Seidelin, J.(2);Burisch, J.(1,3);
Created: Wednesday, 2 June 2021, 4:12 PM
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cremer1, T. Lobaton2, S. Vieujan3, P. Bossuyt4, J.F. Rahier5, F. Baert6, O. Dewit7, M. Somers8, E. Macken8, A. Vijverman9, P. Van Hootegem10, F. Mana11, B. Willandt12, P. Caenepeel13, E. Humblet13, F. D’Heygere14, A. Verreth15, A. El Nawar16, J.L. Coenegrachts17, S. Dewit18, S. De Coninck19, N. Schoofs20, S. Delen21, J. Dutre22, C. Thienpont23, S. Vanden Branden24, D. Staessen25, D. Franchimont1, Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group

Created: Thursday, 30 January 2020, 10:12 AM
P422: COVID 19 infection in IBD patients treated with biologic therapy-experience from tertiary center in Serbia
Year: 2021
Source: ECCO'21 Virtual
Authors: Sokic Milutinovic, A.(1);Jevtovic, M.(2);Jovicic, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P422: How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
Year: 2022
Source: ECCO'22
Authors: Routledge, E.(1);Meade, S.(1);Sharma, E.(1);Zeki, S.(1);Ray, S.(1);Anderson, S.(1);Sanderson, J.(1);Mawdsley, J.(1);Samaan, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P422: Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Alten*1, C. Markland2, K. Kawakami3, M. Boyce4, F. Casty5, R. Muniz5, M. C. Genovese6

Created: Friday, 22 February 2019, 9:41 AM